Related Experiment Video
Updated: Apr 13, 2026

Expression of Transgenes in Native Bladder Urothelium Using Adenovirus-Mediated Transduction
Published on: October 6, 2022
The cAMP responsive element binding protein 1 transactivates epithelial membrane protein 2, a potential tumor
Chien-Feng Li1,2,3, Wen-Jeng Wu4,5,6,7, Wen-Ren Wu8
1Department of Pathology, Chi Mei Medical Center, Tainan, Taiwan.
Abstract:
In this study, we report that EMP2 plays a tumor suppressor role by inducing G2/M cell cycle arrest, suppressing cell viability, proliferation, colony formation/anchorage-independent cell growth via regulation of G2/M checkpoints in distinct urinary bladder urothelial carcinoma (UBUC)-derived cell lines. Genistein treatment or exogenous expression of the cAMP responsive element binding protein 1 (CREB1) gene in different UBUC-derived cell lines induced EMP2 transcription and subsequent translation. Mutagenesis on either or both cAMP-responsive element(s) dramatically decreased the EMP2 promoter activity with, without genistein treatment or exogenous CREB1 expression, respectively. Significantly correlation between the EMP2 immunointensity and primary tumor, nodal status, histological grade, vascular invasion and mitotic activity was identified. Multivariate analysis further demonstrated that low EMP2 immunoexpression is an independent prognostic factor for poor disease-specific survival. Genistein treatments, knockdown of EMP2 gene and double knockdown of CREB1 and EMP2 genes significantly inhibited tumor growth and notably downregulated CREB1 and EMP2 protein levels in the mice xenograft models. Therefore, genistein induced CREB1 transcription, translation and upregulated pCREB1(S133) protein level. Afterward, pCREB1(S133) transactivated the tumor suppressor gene, EMP2, in vitro and in vivo. Our study identified a novel transcriptional target, which plays a tumor suppressor role, of CREB1.
Insights
The EMP2 gene acts as a tumor suppressor in urothelial carcinoma by halting cell cycle progression. Genistein treatment activates CREB1, which then boosts EMP2 expression, inhibiting tumor growth.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Urinary bladder urothelial carcinoma (UBUC) is a significant health concern.
- The role of EMP2 in UBUC progression requires further elucidation.
- Understanding molecular pathways is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the tumor suppressor role of EMP2 in UBUC.
- To explore the regulatory mechanism of EMP2 expression by CREB1 and genistein.
- To assess the prognostic significance of EMP2 in UBUC patients.
Main Methods:
- Cell culture of UBUC-derived cell lines.
- Gene expression analysis (transcription and translation).
- Reporter assays, mutagenesis, and Western blotting.
- Immunohistochemistry and survival analysis.
- In vivo xenograft models in mice.
Main Results:
- EMP2 induces G2/M cell cycle arrest and suppresses UBUC cell viability, proliferation, and anchorage-independent growth.
- Genistein and CREB1 expression upregulate EMP2 transcription and translation.
- EMP2 immunointensity correlates with favorable clinicopathological features and survival.
- Low EMP2 expression is an independent predictor of poor disease-specific survival.
- Genistein treatment inhibits tumor growth in vivo by upregulating CREB1 and EMP2.
Conclusions:
- EMP2 functions as a tumor suppressor in UBUC by regulating cell cycle checkpoints.
- CREB1 acts as a transcriptional activator of EMP2, and genistein enhances this pathway.
- EMP2 is a novel prognostic biomarker and potential therapeutic target for UBUC.
More Related Videos
Related Concept Videos
Master Transcription Regulators
RNA Polymerase II Accessory Proteins
Cell Specific Gene Expression
Urinary Bladder
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
Abnormal Proliferation
Eukaryotic Transcription Activators
The binding domains are capable of recognizing and interacting with regulatory sequences on the DNA. These...

